Generic Xdemvy Availability
Last updated on Jan 8, 2025.
Xdemvy is a brand name of lotilaner ophthalmic, approved by the FDA in the following formulation(s):
XDEMVY (lotilaner - solution/drops;ophthalmic)
-
Manufacturer: TARSUS
Approval date: July 24, 2023
Strength(s): 0.25% [RLD]
Has a generic version of Xdemvy been approved?
No. There is currently no therapeutically equivalent version of Xdemvy available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xdemvy. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Methods for treating ocular demodex using isoxazoline parasiticide formulations
Patent 10,835,517
Issued: November 17, 2020
Inventor(s): Azamian Bobak Robert & Ackermann Douglas Michael & Hickok Shawn D. & Vehige Joseph G.
Assignee(s): Tarsus Pharmaceuticals, Inc.Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.
Patent expiration dates:
- December 14, 2038✓
- December 14, 2038
-
Isoxazoline parasiticide formulations and methods for treating blepharitis
Patent 11,197,847
Issued: December 14, 2021
Inventor(s): Azamian Bobak Robert & Ackermann Douglas Michael & Hickok Shawn D. & Vehige Joseph G.
Assignee(s): Tarsus Pharmaceuticals, Inc.Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.
Patent expiration dates:
- December 14, 2038✓
- December 14, 2038
-
Patent 11,690,826
Patent expiration dates:
- December 14, 2038✓
- December 14, 2038
-
Patent 11,690,827
Patent expiration dates:
- December 14, 2038✓
- December 14, 2038
-
Patent 11,752,137
Patent expiration dates:
- December 14, 2038✓
- December 14, 2038
-
Isoxazoline derivatives as pesticides
Patent 8,383,659
Issued: February 26, 2013
Inventor(s): Nanchen Steve & Gauvry Noëlle & Goebel Thomas
Assignee(s): Novartis AGNovel isoxazoline compounds and compositions containing the compounds are disclosed. The compounds have pesticidal properties and are suitable for use on non-human animals.
Patent expiration dates:
- January 17, 2030✓✓
- January 17, 2030
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- July 24, 2028 - NEW CHEMICAL ENTITY
More about Xdemvy (lotilaner ophthalmic)
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: ophthalmic anti-infectives
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.